Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 1/20 | 1.00 |
| ▸ | ABCC8 | Q09428 | 1/20 | 1.00 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 1.00 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 1.00 |
| ▸ | PLK1 | P53350 | 11/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.45 |
| ▸ | CDC7 | O00311 | 2/20 | 0.45 |
| ▸ | PLK4 | O00444 | 2/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.45 |
| ▸ | PIM1 | P11309 | 2/20 | 0.45 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | PRKX | P51817 | 2/20 | 0.45 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.45 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.45 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.45 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6024203 | 1.00 | ABCC9 (1.00) | ABCC9ABCC8KCNJ11KCNJ8PLK1 | |
| SCHEMBL8587558 | 0.84 | ABCC9 (0.73) | ABCC9ABCC8KCNJ11KCNJ8PLK1 | |
| SCHEMBL8609262 | 0.84 | ABCC9 (0.73) | ABCC9ABCC8KCNJ11KCNJ8PLK1 | |
| SCHEMBL8870945 | 0.84 | ABCC9 (0.72) | ABCC9ABCC8KCNJ11KCNJ8PLK1 | |
| SCHEMBL8870947 | 0.84 | ABCC9 (0.72) | ABCC9ABCC8KCNJ11KCNJ8PLK1 | |
| SCHEMBL7887074 | 0.83 | ABCC9 (0.71) | ABCC9ABCC8KCNJ11KCNJ8PLK1 | |
| SCHEMBL8670505 | 0.82 | ABCC9 (0.70) | ABCC9ABCC8KCNJ11KCNJ8PLK1 | |
| SCHEMBL8670509 | 0.82 | ABCC9 (0.70) | ABCC9ABCC8KCNJ11KCNJ8PLK1 | |
| SCHEMBL7347226 | 0.78 | PLK1 (0.67) | ABCC9ABCC8KCNJ11KCNJ8PLK1 | |
| SCHEMBL8372683 | 0.78 | PLK1 (0.67) | ABCC9ABCC8KCNJ11KCNJ8PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0729457-B1 | DIAMINOCYCLOBUTENE-3,4-DIONES AS SMOOTH MUSCLE RELAXANTS | AMERICAN HOME PROD (US) | 1998-12-23 | — | — | EP | claimed |
| US-5506252-A | MUSCLE RELAXANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-04-09 | — | — | US | claimed |
| US-12605367-B2 | Methods of treatment and/or prevention of disorders and symptoms related to BKCa and/or SK channelophathies | Universite de Bordeaux (FR) | 2026-04-21 | — | — | US | disclosed |
| US-20220313664-A1 | METHODS OF TREATMENT AND/OR PREVENTION OF DISORDERS AND SYMPTOMS RELATED TO BKCA AND/OR SK CHANNELOPHATHIES | ASSETSUP (FR) | 2022-10-06 | — | — | US | disclosed |
| US-20220265282-A1 | USE OF REMOTE ISCHEMIC CONDITIONING FOR TRAUMATIC INJURY | THE HOSPITAL FOR SICK CHILDREN (CA) | 2022-08-25 | — | — | US | disclosed |
| EP-4031134-A1 | METHODS OF TREATMENT AND/OR PREVENTION OF DISORDERS AND SYMPTOMS RELATED TO BKCA AND/OR SK CHANNELOPHATHIES | UNIVERSITE DE BORDEAUX (FR) | 2022-07-27 | — | — | EP | disclosed |
| US-8591947-B2 | Dual controlled release dosage form | Osmotica Kereskedelmi és Szolgáltató KFT (HU) | 2013-11-26 | — | — | US | disclosed |
| US-20130108693-A1 | Dual Controlled Release Dosage Form | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2013-05-02 | — | — | US | disclosed |
| US-8329217-B2 | Dual controlled release dosage form | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2012-12-11 | — | — | US | disclosed |
| US-8241667-B2 | Dual controlled release osmotic device | Osmotica Kereskedelmi és Szolgáltató KFT (HU) | 2012-08-14 | — | — | US | disclosed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| EP-0796243-B1 | DIAMINOCYCLOBUTENE-3,4-DIONES | AMERICAN HOME PROD (US) | 1999-01-27 | — | — | EP | disclosed |
| EP-0729457-B1 | DIAMINOCYCLOBUTENE-3,4-DIONES AS SMOOTH MUSCLE RELAXANTS | AMERICAN HOME PROD (US) | 1998-12-23 | — | — | EP | disclosed |
| WO-1998011888-A1 | METHOD OF TREATING URINARY INCONTINENCE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-03-26 | — | — | WO | disclosed |
| EP-0796243-A1 | DIAMINOCYCLOBUTENE-3,4-DIONES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-09-24 | — | — | EP | disclosed |
| EP-0729457-A1 | DIAMINOCYCLOBUTENE-3,4-DIONES AS SMOOTH MUSCLE RELAXANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-09-04 | — | — | EP | disclosed |
| US-5530025-A | SMOOTH MUSCLE RELAXANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-06-25 | — | — | US | disclosed |
| WO-1996015103-A1 | DIAMINOCYCLOBUTENE-3,4-DIONES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
| US-5506252-A | MUSCLE RELAXANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| WO-1995014005-A1 | DIAMINOCYCLOBUTENE-3,4-DIONES AS SMOOTH MUSCLE RELAXANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | PYGB, PC, KCNN3 | ABCC9 384/4885ABCC8 415/4885KCNJ11 18/4885 |
| US-12605367-B2 | Methods of treatment and/or prevention of disorders and symptoms related to BKCa and/or SK channelophathies | KCNN3, KCNN1, KCNN2 | ABCC9 1065/4885ABCC8 1310/4885KCNJ11 9/4885 |
| US-20220313664-A1 | METHODS OF TREATMENT AND/OR PREVENTION OF DISORDERS AND SYMPTOMS RELATED TO BKCA AND/OR SK CHANNELOPHATHIES | KCNN3, KCNN1, KCNN2 | ABCC9 2208/4885ABCC8 2726/4885KCNJ11 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.